This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Myelomalacia

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Myelomalacia is seen as an ill-defined area of abnormal cord that can be visualised on MRI

  • myelomalacia is thought to occur at sites of cord oedema
  • may be associated with focal atrophy and has been described in patients as early as 2 months post injury
  • myelomalacia is the second most common finding in patients imaged more than 20 years after injury, with a prevalence of 55%. Approximately 75% of patients will have a complete spinal cord injury [1]
  • myelomalacia may be associated with syrinx formation [1,2]
  • MRI showing myelomalacia following spinal cord injury
    • seen as an ill-defined area of abnormal cord, which is hypointense on T1 (but hyperintense to CSF) and hyperintense on T2 compared with normal cord

Reference:

  • 1) Wang D, Bodley R, Sett P, Gardner B, Frankel H. A clinical magnetic resonance imaging study of the traumatised spinal cord more than 20 years following injury. Paraplegia 1996;34:65-81
  • 2) Curati WL, Kingsley DPE, Kendall BE, Moseley IF. MRI in chronic spinal cord trauma. Neuroradiology 1992;35:30-5.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.